학술논문
Fusobacterium nucleatumsupresses anti-tumor immunity by activating CEACAM1
Document Type
Article
Author
Source
OncoImmunology; June 2019, Vol. 8 Issue: 6
Subject
Language
ISSN
21624011; 2162402X
Abstract
ABSTRACTFusobacterium nucleatum (F. nucleatum) is an oral anaerobe found to be enriched in colorectal cancer (CRC). Presence of F. nucleatumin CRC has been correlated with resistance to chemotherapy and poor prognosis. We previously demonstrated that the Fap2 outer-surface protein of F. nucleatumbinds and activates the human inhibitory receptor TIGIT which is expressed by T and Natural Killer (NK) cells, and inhibits anti-tumor immunity. Here we show that F. nucleatumalso binds and activates the human inhibitory receptor CEACAM1 leading to inhibition of T and NK cells activities. Our results suggest that using CEACAM1 and TIGIT inhibitors and specific targeting of fusobacteria should be considered for treating fusobacteria-colonized tumors